Patents by Inventor James Robert Blinn

James Robert Blinn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLOPYRIMIDINE ITK INHIBITORS
    Publication number: 20240132505
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: October 24, 2023
    Publication date: April 25, 2024
    Inventors: Eric Jon JACOBSEN, David Randolph ANDERSON, James Robert BLINN, Susan Landis HOCKERMAN, Richard HEIER, Paramita MUKHERJEE
  • SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20240067643
    Abstract: The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Application
    Filed: July 3, 2023
    Publication date: February 29, 2024
    Inventors: David Randolph ANDERSON, Susan Landis HOCKERMAN, James Robert BLINN, Eric Jon JACOBSEN
  • REV-ERB AGONISTS
    Publication number: 20240002380
    Abstract: Disclosed are compounds that regulate REV-ERB nuclear receptors that would be useful for treatment of various diseases. These compounds may be used in therapeutic applications such as in the treatment of neurodegenerative disease such as anxiety disorder, autoimmune diseases or disorders, or muscular disorders such as sarcopenia.
    Type: Application
    Filed: April 13, 2023
    Publication date: January 4, 2024
    Applicants: Saint Louis University, Pelagos Pharmaceuticals, Inc.
    Inventors: John K. Walker, Thomas Patrick Burris, Sadichha Sitaula, Arindam Chatterjee, Napoleon Clement D'Cunha, Eric Jon Jacobsen, James Robert Blinn
  • Pyrrolopyrimidine ITK inhibitors
    Patent number: 11820775
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: November 21, 2023
    Assignee: Aclaris Therapeutics, Inc.
    Inventors: Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Susan Landis Hockerman, Richard Heier, Paramita Mukherjee
  • Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
    Patent number: 11739086
    Abstract: The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: August 29, 2023
    Assignee: Aclaris Therapeutics, Inc.
    Inventors: David Randolph Anderson, Susan Landis Hockerman, James Robert Blinn, Eric Jon Jacobsen
  • SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS
    Publication number: 20220372034
    Abstract: The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 24, 2022
    Inventors: Eric Jon JACOBSEN, David Randolph ANDERSON, James Robert BLINN, Paramita MUKHERJEE, Paul CHANGELIAN, Canxin XU
  • PYRROLOPYRIMIDINE ITK INHIBITORS
    Publication number: 20220348579
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: April 21, 2021
    Publication date: November 3, 2022
    Inventors: Eric Jon JACOBSEN, David Randolph ANDERSON, James Robert BLINN, Susan Landis HOCKERMAN, Richard HEIER, Paramita MUKHERJEE
  • Substituted pyrrolopyridines as JAK inhibitors
    Patent number: 11420966
    Abstract: The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: August 23, 2022
    Inventors: Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Paramita Mukherjee, Paul Changelian, Canxin Xu
  • SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS
    Publication number: 20220235043
    Abstract: The present invention relates to new sulfonamide pyrrolopyridine compounds and compositions useful in the treatment of JAK-mediated conditions having the structures of Formula (I), wherein the R groups are as defined in the detailed description. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided. Exemplary indications treated by inhibition of JAK kinase activity include, but are not limited to, inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, and Celiac disease.
    Type: Application
    Filed: July 31, 2020
    Publication date: July 28, 2022
    Inventors: David Randolph ANDERSON, Eric Jon JACOBSEN, James Robert BLINN, Susan Landis HOCKERMAN, Paramita MUKHERJEE, Paul CHANGELIAN
  • SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20210284637
    Abstract: The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 16, 2021
    Inventors: David Randolph ANDERSON, Susan Landis HOCKERMAN, James Robert BLINN, Eric Jon JACOBSEN
  • Pyrrolopyrimidine ITK inhibitors
    Patent number: 11021482
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: June 1, 2021
    Assignee: Adaris Therapeutics, Inc.
    Inventors: Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Susan Landis Hockerman, Richard Heier, Paramita Mukherjee
  • Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
    Patent number: 10981906
    Abstract: The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: April 20, 2021
    Assignee: ACLARIS THERAPEUTICS, INC.
    Inventors: David Randolph Anderson, Susan Landis Hockerman, James Robert Blinn, Eric Jon Jacobsen
  • SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS
    Publication number: 20200347053
    Abstract: The present invention relates to new pyrrolopyridine compounds having the structures of Formula (I)-(IV), wherein the R groups, A, B, C, D and n are as defined in the detailed description, and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Application
    Filed: May 4, 2020
    Publication date: November 5, 2020
    Inventors: Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Paramita Mukherjee, Paul Changelian, Canxin Xu
  • Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
    Patent number: 10800775
    Abstract: The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: October 13, 2020
    Assignee: ACLARIS THERAPEUTICS, INC.
    Inventors: David Randolph Anderson, Susan Landis Hockerman, James Robert Blinn, Eric Jon Jacobsen
  • PYRROLOPYRIMIDINE ITK INHIBITORS
    Publication number: 20200048262
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: August 12, 2019
    Publication date: February 13, 2020
    Inventors: Eric Jon JACOBSEN, David Randolph ANDERSON, James Robert BLINN, Susan Landis HOCKERMAN, Richard HEIER, Paramita MUKHERJEE
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20200039960
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 6, 2020
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, Jr., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • PYRROLOPYRIMIDINE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER
    Publication number: 20190352300
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Application
    Filed: April 24, 2019
    Publication date: November 21, 2019
    Applicant: ACLARIS THERAPEUTICS, INC.
    Inventors: Eric Jon Jacobsen, James Robert Blinn, John Robert Springer, Susan Landis Hockerman, David Randolph Anderson
  • Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer
    Patent number: 10316038
    Abstract: Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R1, R2, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: June 11, 2019
    Assignee: ACLARIS THERAPEUTICS, INC.
    Inventors: Eric Jon Jacobsen, James Robert Blinn, John Robert Springer, Susan Landis Hockerman, David Randolph Anderson
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20190144429
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: January 30, 2019
    Publication date: May 16, 2019
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Gõran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, JR., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20190135808
    Abstract: The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
    Type: Application
    Filed: November 2, 2018
    Publication date: May 9, 2019
    Inventors: David Randolph ANDERSON, Susan Landis HOCKERMAN, James Robert BLINN, Eric Jon JACOBSEN